In Section C, individuals will receive ABBV-744 and oral navitoclax. In Segment D, members will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment till disease progression or perhaps the contributors are unable to tolerate the study drugs. Celastrol was identified as a Myb inhib